The Silent Sales Funnel Behind Osteoporosis Treatment

Osteoporosis has become one of the most heavily medicalized conditions in modern healthcare, driving billions of dollars in annual sales of bisphosphonate drugs like alendronate (Fosamax), zoledronic acid, and denosumab. The narrative is straightforward and compelling: bones weaken with age, especially in postmenopausal women; bone density scans (DEXA) reveal the extent of this weakening; and bisphosphonate drugs reduce fracture risk.

But like many compelling narratives in medicine, this one is more complicated than it appears. A closer examination of the osteoporosis screening and treatment industry reveals a system in which financial interests, inflated risk estimates, and the medicalization of normal aging have driven overdiagnosis and overtreatment on a massive scale.

The Creation of a Diagnosis

The concept of osteoporosis as a disease to be screened for and treated was significantly shaped by the development of DEXA scanning technology and the pharmaceutical industry's subsequent investment in promoting its use. The diagnostic thresholds that define "osteoporosis" and "osteopenia" (low bone density) were established using reference populations that have been criticized for being non-representative of many patients who now receive these diagnoses.

Critically, the relationship between bone mineral density (BMD) as measured by DEXA and actual fracture risk is less straightforward than commonly presented. BMD explains only a portion of fracture risk; other factors including fall risk, bone microarchitecture, muscle strength, and coordination play important roles that DEXA cannot measure. Many patients with "normal" bone density experience fractures, while many with low BMD never do.

The Benefits and Risks of Bisphosphonates

Bisphosphonate drugs do reduce fracture risk in women who have already sustained osteoporotic fractures and in women with very low bone density. However, their benefit in women with osteopenia (the more common, less severe diagnosis) is substantially less clear, and the absolute risk reduction for fractures in lower-risk populations is modest.

Against these limited benefits must be weighed the genuine risks of long-term bisphosphonate use. Osteonecrosis of the jaw (ONJ)—a severe and difficult-to-treat condition in which bone in the jaw dies and is exposed—is a recognized complication of bisphosphonate therapy, particularly in patients undergoing dental procedures. Atypical femoral fractures, a paradoxical side effect in which the mid-shaft of the femur fractures after minimal trauma in patients on long-term bisphosphonates, represent a serious complication that can cause significant morbidity.

Beyond Pharmaceuticals: The Bone Health Evidence Base

What is often lost in the osteoporosis treatment narrative is the substantial evidence base for non-pharmaceutical interventions in bone health. Weight-bearing and resistance exercise are consistently among the most effective interventions for maintaining bone density, improving balance, reducing fall risk, and ultimately preventing fractures.

Adequate calcium and vitamin D are prerequisites for bone health, but the evidence suggests that optimal bone health also requires a broader array of nutrients including magnesium, vitamin K2, boron, and adequate protein. The gut microbiome plays a role in calcium absorption and bone metabolism that is receiving increasing research attention.

Fall Prevention: The Overlooked Priority

Perhaps the most important and consistently overlooked aspect of osteoporotic fracture prevention is fall prevention. The vast majority of osteoporotic fractures occur as a result of falls. Interventions that reduce fall risk—including strength and balance training, medication review to reduce polypharmacy and medications that increase fall risk, home environment modification, and vision correction—may have a greater impact on fracture rates than drug therapy alone.

Yet fall prevention receives a fraction of the clinical attention and research investment devoted to pharmaceutical management of bone density. This reflects a systemic bias in medicine toward interventions that generate pharmaceutical revenue over those that require lifestyle modification and multidisciplinary care.

A More Honest Conversation About Bone Health

Patients diagnosed with osteoporosis or osteopenia deserve an honest, individualized conversation about their actual fracture risk, the evidence base for available interventions, and the real risks and benefits of pharmaceutical treatment. For many patients, particularly those with osteopenia and no prior fractures, the risk-benefit calculation may not favor pharmaceutical treatment.

A more holistic approach to bone health—emphasizing resistance exercise, nutritional optimization, fall prevention, and careful risk stratification—may achieve better outcomes for many patients with fewer adverse effects than the current pharmaceutical-first model.

Subscribe to Goldcare to access the full library of health insights ›